**Supplementary Table 1. Demographic characteristics and clinical features in our patient cohort.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Training group****(*n=*290)** | **Internal****validation group** **(*n=*291)** | **External****validation group** **(n=106)** | ***p*-value** |
| Age (years) | 37.64±10.71 | 38.26±10.45 | 37.99±10.52 | 0.780 |
| Sex | Male | 184 (63.4%) | 184 (63.2%) | 69 (65.1%) | 0.941 |
| Female | 106 (36.6%) | 107 (36.8%) | 37 (34.9%) |
| Total bilirubin (μmol/L)  | 15.03±8.35 | 14.21±10.27 | 14.78± 6.36 | 0.234 |
| Albumin (g/L) | 42.06±5.16 | 43.13±4.78 | 43.30±4.89 | 0.014 |
| ALT (U/L) | 25.67±7.79 | 26.82±7.78 | 22.25±12.77 | 0.024 |
| AST (U/L) | 23.03±6.17 | 24.15±6.57 | 25.23±9.95 | 0.015 |
| GGT (U/L) | 23.03±14.37 | 23.83±15.45 | 23.17±15.40 | 0.844 |
| WBC (109/L) | 5.82±1.46 | 5.71±1.55 | 5.72±1.48 | 0.651 |
| PLT (109/L) | 209.50±55.98 | 207.20±54.63 | 209.75±46.00 | 0.855 |
| HBsAg (Log IU/mL) | 3.40±0.98 | 3.38±1.06 | 4.10±0.75 | <0.001 |
| HBV DNA (Log IU/mL) | 5.36±1.97 | 5.67±2.10 | 6.16±1.90 | 0.007 |
| PT (s) | 12.62±1.03 | 13.02±1.15 | 11.53±0.82 | 0.007 |
| INR | 1.01±0.07 | 1.02±0.08 | 1.05±0.07 | <0.001 |
| APRI | 0.30±0.14 | 0.32±0.15 | 0.31±0.15 | 0.227 |
| FIB-4 | 0.92±0.55 | 0.98±0.56 | 0.86±0.45 | 0.187 |
| METAVIR fibrosis (*n* %)  | stage |  |  | <0.001 |
| F0 | 42 (14.5) | 35 (12.0) | 49 (46.2) |  |
| F1 | 159 (54.8) | 155 (53.3) | 24 (22.7) |  |
| F2 | 61 (21.0) | 64 (22.0) | 18 (17.0) |  |
| F3 | 18 (6.2) | 27 (9.3) | 7 (6.6) |  |
| F4 | 10 (3.5) | 10 (3.4) | 8 (7.5) |  |

Data are *n* (%) or mean±SEM. ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transpeptidase; TCHO, total cholesterol; CHE, cholinesterase; WBC, white blood cell count; PLT, platelet count; HBV, hepatitis B virus; PT, prothrombin time; INR, international normalized ratio.